Voyager Therapeutics, Inc. (VYGR)
After hours:
| Previous close | 8.44 |
| Open | 8.50 |
| Bid | 8.41 x 200 |
| Ask | 8.47 x 100 |
| Day's range | 8.25 - 8.56 |
| 52-week range | 6.06 - 14.34 |
| Volume | |
| Avg. volume | 670,693 |
| Market cap | 459.037M |
| Beta (5Y monthly) | 0.98 |
| PE ratio (TTM) | 2.84 |
| EPS (TTM) | 2.97 |
| Earnings date | 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.78 |
GlobeNewswireVoyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding - - Preclinical safety and efficacy demonstrated in Alzheimer’s disease and ALS gene therapies; low IV doses provided broad CNS biodistribution and robust transduction of key cell types - LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neu
Simply Wall St.Voyager Therapeutics' (NASDAQ:VYGR) three-year earnings growth trails the splendid shareholder returns
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- GlobeNewswire
Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast
LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report first quarter 2024 financial and operating results after market close on Monday, May 13, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results. To participate via telephone and join the call live, please register in advance
